Clinical Trials

I am a person who has had to remain in “maintenance” chemo for almost seven years. During this time I have grown to deeply appreciate the caregiving and caring provided at PVHO.


Myelodysplastic Syndrome:

TetraLogic 0087
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination with 5-azacitidine in Subjects with Myelodysplastic Syndrome who are Naïve, Refractory, or have Relapsed to 5-azacitidine Therapy.


Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia:

TetraLogic 0094
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.


Pancreatic Cancer:

Incyte INCB18424-362
A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy.


Non Hodgkin Lymphoma:

Infinity IPI-145-06
A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma.


Triple-Negative Breast Cancer:

Celldex CDX011-04
The primary objective of the study is to evaluate the anti-cancer activity of CDX-011 in metastatic, GPNMB over-expressing, triple-negative breast cancer as measured by the duration of progression-free survival (PFS).


HER2-Positive Breast Cancer:

Merrimack MM-302-02-02-03
Patients with incurable, unresectable, locally advanced/metastatic HER2-positive breast cancer patients who have received prior treatment with trastuzumab in any setting and who have either progressed on or are intolerant to each of pertuzumab and ado-trastuzumab emtansine in the metastatic or locally advanced setting. Patients must not have been previously treated with an anthracycline in any setting.


Triple Negative Breast Cancer:

Celgene ABI-007-MBC-001
First-line treatment of subjects with triple negative metastatic breast cancer (TNMBC), defined as estrogen receptor (ER) negative, progesterone receptor (PgR) negative, and human epidermal growth factor receptor 2 (HER2) negative.


Non Small Cell Lung Cancer:

Celgene ABI-007-NSCL-003
This is a Phase III, randomized, open-label, cross-over, multi-center study of nab-paclitaxel or best supportive care (BSC) as maintenance treatment after response or SD with nab-paclitaxel plus carboplatin as induction in subjects with squamous cell NSCLC. Once a subject in the BSC arm during the Maintenance part of the study
experiences radiologic progression of disease, they will be eligible to cross-over to receive nabpaclitaxel.

Genentech MO22097
An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care ± continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy.


For questions or for more information please contact us at your preferred location, or schedule an appointment with one of our medical oncologists.

Contact Us Now

SCHEDULE APPOINTMENT or seeking SECOND OPINION? Complete this form and we will contact you within 24-hours.

Awards & Recognition